Non-Hispanic Black and Hispanic/Latino children were also significantly less likely to receive brain MRI scans compared with ...

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

Panelists discuss how therapy sequencing is approached for patients with chronic lymphocytic leukemia (CLL), with a focus on ...

Panelists discuss the benefits of implementing bispecific therapy programs in the community setting as well as factors ...

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...

Debra Patt, MD, PhD, MBA, MPH, warns that prior authorization barriers are delaying critical cancer treatments and urges a ...

Access and affordability are among the top priorities in health care for Americans who participated in the survey.

Women living in rural Appalachia who are at high-risk of HIV had effective interventions delivered through Facebook.

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.

Panelists discuss how hypophosphatemia can cause both acute effects like muscle weakness and confusion and chronic ...